SCHEMBL3338952

SCHEMBL3338952

[CH2]CCCC/C=C/CC(C)C

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3338953 1.00 TRPV1 (0.34) TRPV1TRPM8
SCHEMBL2120465 0.93 TRPV1 (0.32) TRPV1TRPM8
SCHEMBL2120463 0.93 TRPV1 (0.32) TRPV1TRPM8
SCHEMBL2118191 0.82
SCHEMBL2118194 0.82
SCHEMBL2591623 0.81 TSHR (0.42) TRPV1TRPM8
SCHEMBL23566468 0.79 HIF1A (0.41) TRPV1TRPM8
SCHEMBL624026 0.79 TSHR (0.46) TRPV1TRPM8
SCHEMBL23566467 0.79 HIF1A (0.41) TRPV1TRPM8
SCHEMBL19409322 0.79 TSHR (0.46) TRPV1TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1853547-B1 PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION AND STABILIZING METHOD OF CAPSINOID AJINOMOTO KK (JP) 2014-11-12 EP claimed
US-20100152291-A1 PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION, STABILIZING METHOD OF CAPSINOID, AND CAPSINOID COMPOSITION AJINOMOTO CO., INC. (JP) 2010-06-17 US claimed
EP-1853547-A1 PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION, STABILIZING METHOD OF CAPSINOID, AND CAPSINOID COMPOSITION Ajinomoto Co., Inc. (JP) 2007-11-14 EP claimed
US-20070020738-A1 produced in a high yield in a short time using an enzyme; capsinoid can be stably preserved by coexistence of a fatty acid; enables industrially production AJINOMOTO CO., INC (JP) 2007-01-25 US claimed
WO-2006088239-A1 PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION, STABILIZING METHOD OF CAPSINOID, AND CAPSINOID COMPOSITION AJINOMOTO CO., INC. (JP) 2006-08-24 WO claimed
EP-1853547-B1 PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION AND STABILIZING METHOD OF CAPSINOID AJINOMOTO KK (JP) 2014-11-12 EP disclosed
US-20100152291-A1 PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION, STABILIZING METHOD OF CAPSINOID, AND CAPSINOID COMPOSITION AJINOMOTO CO., INC. (JP) 2010-06-17 US disclosed
US-7700331-B2 Production method of capsinoid by dehydrating condensation, stabilizing method of capsinoid, and capsinoid composition AJINOMOTO CO., INC. (JP) 2010-04-20 US disclosed
EP-1853547-A1 PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION, STABILIZING METHOD OF CAPSINOID, AND CAPSINOID COMPOSITION Ajinomoto Co., Inc. (JP) 2007-11-14 EP disclosed
US-20070020738-A1 produced in a high yield in a short time using an enzyme; capsinoid can be stably preserved by coexistence of a fatty acid; enables industrially production AJINOMOTO CO., INC (JP) 2007-01-25 US disclosed
WO-2006088239-A1 PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION, STABILIZING METHOD OF CAPSINOID, AND CAPSINOID COMPOSITION AJINOMOTO CO., INC. (JP) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152291-A1 PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION, STABILIZING METHOD OF CAPSINOID, AND CAPSINOID COMPOSITION FADS2, FADS1, FASN TRPV1 1523/4885TRPM8 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.